Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | A sales trend is driving investor worries with AbbVie Inc. (ABBV)ABBV, a pharmaceutical business, had its stock tumble 10.5%. The 52-week low for the stock is $105.56 and the 52-week high is $175.91.
By: Medical Infralytix Pvt Ltd With $4.7 billion in revenue, Humira remained the company's top seller, although sales were down 2% year over year. This comes as no surprise given that the medicine is already up against competition with biosimilar in Europe. Imbruvica's income decline was a different story. The drug's sales fell 7.4% to $1.1 billion, according to ABBV. However, in the long run, the pharmaceutical company's aesthetics and neuroscience brands, as well as revenues from Skyrizi, Rinvoq and Venclexta continue to improve. Aesthetics brought in $1.374 billion in income, up 20.5% from the same time the previous year, while neurology brought in $1.488 billion, up 19.2%. Skyrizi and Rinvoq are both immunology medications that have shown that they can readily compensate for Humira's lost revenues. Skyrizi generated $940 million in revenue in the quarter, up 63.7% year over year, while Rinvoq generated $465 million, up 53.6% year over year, after receiving a label expansion from the FDA to treat adults with ulcerative colitis who have had a poor response to one or more tumour necrosis factor blockers. Venclexta, a blood cancer medication, brought in $473 million in sales, rising 16.9% year over year. Catch up-to-date press release and more at Medical Infralytix Pvt Ltd services, do visit our website at https://meditherma.com/ End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|